Efficacy and safety of glecirasib in solid tumors with <i>KRAS</i> G12C mutation: A pooled analysis of two phase I/II trials

Authors

Institutions

Publication Details

Journal
Cancer Communications
Published
2025-10-02
DOI
https://doi.org/10.1002/cac2.70056
Citations
4
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
6.07
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

Ligang Xing, Guohao Xia, Andrea Wang‐Gillam, Ayala Hubert et al.
4 citations
Cancer Communications
Lung Cancer Treatments and Mutations
6.07
article

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

Ligang Xing, Guohao Xia, Andrea Wang‐Gillam, Ayala Hubert, Diansheng Zhong, Yanhong Gu, Julia Martínez‐Pérez, Yu Yao, Yuli Ding, Chunmei Bai, Wenming Wu, Kuirong Jiang, Sumei Liu, Yanqiu Zhao, Jon Zugazagoitia, Zhengbo Song, Lin Shen, Lin Wu, Zhiyue Rao, Xiang Liu, Antonio Calles, Zhihua Li, Yongsheng Wang, Yongsheng Li, Jian Li, Xueqin Chen, Jing Huang, Ting Deng, Guilan Wen, Xingya Li, Lian Liu
article en
4 citations

Abstract

No abstract available for this paper.
Cancer CommunicationsVol. 45(11)
Nanchang University (CN), Sun Yat-sen University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Sichuan University (CN), Hadassah Medical Center (IL), Jacobi Medical Center (US), Peking Union Medical College Hospital (CN), Tianjin Medical University General Hospital (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Hospital General Universitario Gregorio Marañón (ES), West China Hospital of Sichuan University (CN), Fudan University Shanghai Cancer Center (CN), Peking University Cancer Hospital (CN), Sun Yat-sen Memorial Hospital (CN), Ono Pharmaceutical (United States) (US), Zhejiang Cancer Hospital (CN), Shandong Tumor Hospital (CN), Hospital Universitario 12 De Octubre (ES), Hunan Cancer Hospital (CN), SBI Pharmaceuticals (Japan) (JP), First Affiliated Hospital of Xi'an Jiaotong University (CN), Jiangsu Cancer Hospital (CN), Cancer Hospital of Chinese Academy of Medical Sciences (CN), Henan Cancer Hospital (CN), Ministry of Education (ET), Jiangsu Province Hospital (CN), Hospital Universitario Virgen del Rocío (ES), Chongqing Cancer Hospital (CN), First Affiliated Hospital of Zhengzhou University (CN), Qilu Hospital of Shandong University (CN), Shandong First Medical University (CN), First Affiliated Hospital of Nanchang University (CN), Hangzhou Cancer Hospital (CN), Nanjing Medical University (CN)
Openalex Percentile: Top 3%
Lung Cancer Treatments and Mutations
6.07
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.